Catalym
Developing innovative immunotherapies to transform cancer patients’ lives by effectively engaging their own immune systems to combat this malignant disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $150m | Series D | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
CatalYm is a biotech startup that operates in the field of cancer immunotherapy. The company is focused on developing innovative treatments to overcome resistance to immunotherapy in cancer patients. CatalYm's primary product is a monoclonal antibody called visugromab, which targets a protein called GDF-15. This protein is known to inhibit the immune system's response to cancer, making it harder for existing treatments to work effectively. By neutralizing GDF-15, CatalYm aims to enhance the effectiveness of immunotherapy and provide a new treatment option for cancer patients who have not responded to other therapies.
CatalYm's business model revolves around the research, development, and commercialization of visugromab. The company generates revenue by conducting clinical trials and, upon successful completion, selling the drug to healthcare providers. CatalYm's target market is the vast number of cancer patients who do not benefit from current immunotherapy treatments due to primary or secondary resistance mechanisms.
The company's entrepreneurial team, backed by strong financial support from shareholders, is committed to exploring the potential of reversing GDF-15-mediated immunosuppression. This approach could pave the way for innovative combination therapies for cancer patients with high unmet needs.
Keywords: Cancer Immunotherapy, Biotech Startup, Monoclonal Antibody, GDF-15, Visugromab, Therapy Resistance, Clinical Trials, Healthcare Providers, Entrepreneurial Team, Shareholder Support.